Lower Vitamin B12 Level at Multiple System Atrophy Diagnosis Is Associated With Shorter Survival

Stuart J McCarter1, Elizabeth A Coon1, Rodolfo Savica1

  • 1Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.

Abstract

Insights

Low vitamin B12 levels are linked to shorter survival in patients with Multiple System Atrophy (MSA). This finding suggests vitamin B12 may be a modifiable factor influencing MSA prognosis.

Area of Science:

  • Neuroscience
  • Biochemistry

Background:

  • Multiple system atrophy (MSA) is a progressive neurodegenerative disease characterized by alpha-synuclein aggregation.
  • In vitro research indicates that vitamin B12 might play a role in mitigating neurodegeneration caused by alpha-synuclein.

Purpose of the Study:

  • To investigate the association between serum vitamin B12 levels at the time of MSA diagnosis and patient survival.
  • To identify if vitamin B12 status is a prognostic indicator in MSA.

Main Methods:

  • A cohort of 182 patients diagnosed with MSA at Mayo Clinic were analyzed.
  • Serum vitamin B12 levels were measured at diagnosis, and survival data were collected.
  • Statistical analysis adjusted for known predictors of survival to determine the risk of death associated with vitamin B12 levels.

Main Results:

  • Lower serum vitamin B12 levels (<367 ng/L) at MSA diagnosis were significantly associated with shorter survival (Hazard Ratio [HR], 1.8; 95% Confidence Interval [CI], 1.3-2.7).
  • Other predictors of shorter survival included falls, bladder symptoms, urinary catheter requirement, male sex, and the MSA-P subtype.

Conclusions:

  • Serum vitamin B12 levels at diagnosis are associated with survival outcomes in patients with Multiple System Atrophy.
  • Further research is warranted to explore this relationship and evaluate vitamin B12 as a potential modifiable factor to improve MSA survival.

Related Concept Videos

Vitamins01:30

Vitamins

Vitamins, derived from the Latin word for life, are essential organic substances required in small quantities for optimal growth and overall well-being. Unlike other organic nutrients, vitamins don't act as sources of energy or building materials but rather facilitate these nutrients' utilization by the body. Vitamins are predominantly coenzymes, assisting enzymes in specific chemical actions, like the oxidation of glucose for energy involving B vitamins. Most vitamins are not produced...
2.2K
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
558
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.8K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
689
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
120